Form 4: Ionis Pharmaceuticals Director Spencer Berthelsen Receives Significant Equity Grants

Ionis Pharmaceuticals Director Spencer R. Berthelsen was granted 11,518 non-qualified stock options and 5,220 Restricted Stock Units on July 1, 2025, as part of the company's non-employee director compensation policy.

Summary

• Director Spencer R. Berthelsen of Ionis Pharmaceuticals Inc. received new equity grants on July 1, 2025.
• The grants include 11,518 non-qualified stock options with an exercise price of $39.94.
• Also granted were 5,220 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Ionis common stock or its cash equivalent.
• These grants are part of the Company's Non-Employee Director Compensation Policy, ensuring the director's annual equity compensation for 2025 does not exceed $450,000 based on aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
• Both the stock options and RSUs vest 100% on the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.
• The stock options expire on June 30, 2035.
• RSUs will be delivered to the reporting person on July 15th following their vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard, positive corporate governance practice of compensating non-employee directors with equity, aligning their interests with shareholders. There are no negative financial implications or risks disclosed.

Positives

• The equity grants align the director's incentives with shareholder interests, promoting long-term value creation.
• The compensation policy ensures a structured and transparent approach to director equity awards, capped at $450,000 for 2025 annual equity compensation.
• The long expiration date for the stock options (June 30, 2035) provides a sustained long-term incentive for the director.

Future Outlook

The granted stock options and Restricted Stock Units are scheduled to vest 100% on July 1, 2026, or the date of the next regularly scheduled annual meeting of stockholders, whichever is earlier, providing future equity incentives to the director.

Management Comments

• The grants were made pursuant to the Company's Non-Employee Director Compensation Policy, which adjusts grants downward to ensure annual equity compensation for non-employee directors in 2025 totals no more than $450,000 based on aggregate grant date fair value.

Industry Context

This type of equity grant to non-employee directors is a common practice in the biotechnology and pharmaceutical industry, aligning director incentives with long-term shareholder value creation and retention.

Comparison to Industry Standards

• The practice of granting stock options and Restricted Stock Units to non-employee directors is standard across the pharmaceutical and biotech sectors.
• This compensation structure is comparable to those at companies like Amgen, Gilead Sciences, or Biogen, which also utilize equity-based incentives to attract and retain experienced board members and align their interests with company performance and shareholder returns.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity compensation, potentially leading to better long-term performance and governance.

Next Steps

• Vesting of stock options and Restricted Stock Units on July 1, 2026, or the next annual meeting, whichever is earlier.
• Delivery of Restricted Stock Units on July 15th following their vesting date.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, Spencer R. Berthelsen, Director Compensation, Stock Options, Restricted Stock Units, RSU, Equity Grant, SEC Form 4, Insider Transaction, Corporate Governance